

2022 Competing Interests Disclosure

From FY 2015 to the present, Dr. Robert Langer receives licensing fees (to patents in which he was an inventor on) from, invested in, consults (or was on Scientific Advisory Boards or Boards of Directors) for, lectured (and received a fee), or conducts sponsored research at MIT for which he was not paid for the following entities:

1. 611 Therapeutics
2. Abpro International;
3. Acorda (Formerly Civitas Therapeutics);
4. Aleph Farms;
5. Alivio Therapeutics;
6. Alkermes;
7. Allevi;
8. Alnylam Pharmaceuticals, Inc.;
9. Amgen;
10. aMoon
11. Apotex;
12. Arcadia Biosciences, Inc.;
13. Arsenal Medical;
14. Artificial Cell Technology, Inc.;
15. Avalon-Globocare;
16. BASF Corporation;
17. Bayer;
18. Bilayer Therapeutics;
19. Biogen;
20. BioInnovation Institute (Novo Nordisk Founden);
21. BioTE Medical;
22. Blackstone (Formerly Clarus);
23. Boston Children's Hospital;
24. CBC Group Investment Mgmt Group;
25. Celanese;
26. Celero;
27. Cellink/BICO
28. Cellomics Technology, Llc;
29. Cellular Biomedical;
30. Charles River Laboratories, Inc.;
31. Clontech Laboratories;
32. Combined Therapeutics ("CTx");
33. Conference Forum;
34. Cornell University;
35. Crispr Therapeutics Ag;
36. Crown Bioscience Inc.;
37. Cygnal Therapeutics, Inc.;
38. Daré Biosciences (Formerly Microchips Biotech, Juniper Pharmaceuticals, and Columbia Laboratories);
39. Daros, Inc.
40. DeepBiome;
41. Dewpoint Therapeutics;
42. Dispendix
43. Domain;
44. Eagle Pharmaceuticals;
45. Earli;
46. Edigene Biotechnology, Inc.;
47. Editas Medicine, Inc.;
48. Eli Lilly;
49. Eisai Inc.;
50. Entrega;
51. EpiBone
52. Establishment Labs, SA.
53. Everlywell;
54. Evox Therapeutics, Ltd.;
55. Fate
56. Flagship Pioneering;
57. Frequency Therapeutics, Inc.;
58. GeneLeap Biotech
59. Genemedicine Co Lmtd;
60. GenScript USA Inc;
61. Geneo Medicine;
62. GENUV;
63. Glaxosmithkline Llc;
64. Glycobia;
65. Glympse Bio;

2022 Competing Interests Disclosure

From FY 2015 to the present, Dr. Robert Langer receives licensing fees (to patents in which he was an inventor on) from, invested in, consults (or was on Scientific Advisory Boards or Boards of Directors) for, lectured (and received a fee), or conducts sponsored research at MIT for which he was not paid for the following entities:

66. Goldman Sachs
67. Greenlight Biosciences;
68. HCR (HealthCare Royalty Partners);
69. HKF DNA Technologies;
70. Hopewell Therapeutics;
71. Horizon Discovery Group Plc;
72. Humacyte, Inc.;
73. IBEX Pharmaceuticals, Inc.;
74. Immunai;
75. ImmuneXcite Inc.;
76. Indivor;
77. Institute of Immunology Co. Ltd;
78. Integrated DNA Technologies, Inc.;
79. InVivo Therapeutics;
80. IxBio;
81. J.R. Simplot Company;
82. Jnana Therapeutics;
83. Kala Pharmaceuticals;
84. Kallyope, Inc.;
85. Kendall Capital;
86. Kensa;
87. Kodikaz Therapeutics;
88. KAST (Korean Academy of Science and Technology);
89. Ksq Therapeutics, Inc.;
90. Landsdowne Labs;
91. LikeMinds;
92. Lonza;
93. Luminopia, Inc.;
94. Luye (Shandong luye);
95. Lyndra Therapeutics;
96. Lyra Therapeutics (Formerly "480 Biomedical");
97. Maurice Marie Janot Award 2020
98. McGovern Institute;
99. Medikinetics Co., Ltd.;
100. Merck;
101. MGH Ragon Institute;
102. Micelle;
103. Moderna Therapeutics;
104. Momenta;
105. Muse Biotechnologies Inc.
106. Mylan;
107. N2Tech;
108. Nanobiosym;
109. Nanobiotix;
110. Neochromosone;
111. Neoteny 4 LLP;
112. NextRNA;
113. Newbridge Ventures LLC;
114. Noveome Biotherapeutics, Inc.;
115. Novo Nordisk;
116. Ohio State University;
117. Olivo (acquired by Shiseido)
118. Ovid Therapeutics;
119. Particles for Humanity;
120. Pfizer, Inc.;
121. Pioneer Hi-Bred International, Inc.;
122. Placon Therapeutics
123. Polaris Partners;
124. Portal Instruments;
125. Preceres, Llc (Acquired by Monsanto);
126. PrognomIQ Inc.;
127. Pulmatrix;
128. PureTech;
129. Quris
130. ReLive;
131. Reprocell Usa, Inc. (Formerly Stemgent);

2022 Competing Interests Disclosure

From FY 2015 to the present, Dr. Robert Langer receives licensing fees (to patents in which he was an inventor on) from, invested in, consults (or was on Scientific Advisory Boards or Boards of Directors) for, lectured (and received a fee), or conducts sponsored research at MIT for which he was not paid for the following entities:

132. Rubius Therapeutics;
133. SBEF (Seoul Bio Economy Forum);
134. Secant Medical, Inc.;
135. Seer, Inc.;
136. Selecta Biosciences;
137. Senses LLC;
138. Setsuro Tech Inc.;
139. Seventh Sense Biosystems, Inc.;
140. Shenzhen Rice Life Technology, Ltd;
141. Shire Ag;
142. Sigilon;
143. Sigma Aldrich Co. Llc;
144. Sio2;
145. Ske S.R.L.;
146. Soil Culture Solutions Llc (Dba Soilcea);
147. Souffle Therapeutics
148. SQZ Biotechnologies;
149. StemBioSys, Inc.;
150. SuonoBio;
151. T2 Biosystems;
152. Taconic Biosciences, Inc. (formerly Taconic Farms);
153. Taiwania Capital (Bio-Asia Taiwan Symposium);
154. TARA;
155. Tarveda Therapeutics;
156. Teal Bio
157. Terasaki Institute
158. Tesio Pharmaceuticals
159. Third Rock Ventures;
160. Tiba Biotech LLC;
161. TissiuM (formerly "Gecko");
162. Transgenic Inc.;
163. Translate Bio (Formerly Rana Therapeutics, Inc.);
164. Trilink Biotechnologies, Inc.;
165. Unilever (Living Proof);
166. University of Bergen, Norway (Falch Lecture Honorarium);
167. VasoRX;
168. Verseau Therapeutics, Inc.;
169. Virex Health
170. Vitakey;
171. Vivtex Corporation;
172. Whitehead Institute;
173. Wiki Foods;
174. Xenter;
175. YourBio (Formerly 7th Sense Biosystems)
176. Yz Biosciences (Guangzhou) Inc.;
177. Zenomics;